Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Vedolizumab Better At Inducing Response In Ulcerative Colitis Than Crohn’s Disease

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Though the initial effects were better in the GEMINI I study in ulcerative colitis than in the GEMINI II study in Crohn’s, the effects of the selective integrin antagonist became more evident by week 28 during the maintenance phase of that trial, researchers note in the New England Journal of Medicine.

You may also be interested in...



Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD

Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.

FDA Approves Simponi For Ulcerative Colitis

J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.

Inflammatory Bowel Drugs To Go Head-To-Head With PCORI Funding

A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.

Topics

Related Companies

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel